Alok Khorana, MD
Cleveland Clinic Main Campus
Treatment & Services
- Cancer Center
Specialty in Diseases & Conditions
- Ampullary Cancer
- Ampullary Carcinoma
- Anal Cancer
- Bile Duct Cancer
- Cancer - Duodenum
- Cancer - Esophagus
- Cancer - Gastric
- Cancer of the Colon, Rectum and Anus
- Carcinoid Syndrome
- Carcinoma of the Colon
- Carcinoma of the small and large bowel
- Colon Cancer
- Colorectal Cancer
- Colorectal Cancer Research
- Esophageal Cancer
- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer
- Gastric Cancer
- Gastrointestinal Malignancies
- Intestinal Carcinoid Tumors
- Large Bowel Cancer
- Large Intestine Cancer
- Neuroendocrine Carcinoma
- Neuroendocrine Tumors
- Pancreatic Cancer
- Pancreatic Endocrine Tumors
- Small Bowel Cancer
- Small Intestine Cancer
- Stomach Cancer
Is Cleveland Clinic Part of Your Insurance?
Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.View All Plans
About Alok Khorana, MD
Dr. Khorana is Professor of Medicine, Cleveland Clinic Lerner College of Medicine, CaseWestern Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical Services of the Taussig Cancer Institute and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic. His clinical and translational research program focuses on new therapeutics and outcomes prediction in gastrointestinal cancers and cancer-associated thrombosisand has been funded by grants from the National Cancer Institute, the NationalHeart, Lung, and Blood Institute, the Porter Family Fund, the Scott HamiltonCARES Initiative, the V Foundation and industry.
Dr. Khorana received his medical degree from Maharaja Sayajirao University Medical Baroda (Gujarat), India. His postdoctoral training included a residency in internal medicine at the University at Buffalo in New York and a fellowship in hematology/oncology atthe University of Rochester, New York. He is a Fellow of the American College of Physicians.
Dr. Khorana is Chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel (CPGC), Chair ofASCO CPGC’s Pancreas Cancer Working Group and Co-Chair of the ASCO Guidelines Panel on Resectable Pancreas Cancer. He also served on the ASCO Scientific Program Committee, multiple ASCO Guidelines Panels and the GI committees of the Southwest Oncology Group and American College of Surgeons Oncology Group. He is immediate past Chair of the International Society on Thrombosis and Haemostasis Scientific Subcommittee on Hemostasis and Malignancy He has previously served as a member of the US Pharmacopoeia Oncology Expert Committee. Co-editor of the book Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention and Treatment(Informa, 2007), Dr. Khorana scientific work has been published in a variety ofscientific journals including New England Journal of Medicine, JAMA, Journal of Clinical Oncology, Blood, Journal of the National Cancer Institute, Clinical Cancer Research, PLoS One, and JAMA Internal Medicine. Heis an associate editor of the journal Cancer Investigation. He hasco-authored chapters in multiple textbooks including Cecil Essentials of Medicine and DeVita Cancer: Principles and Practice of Oncology. Dr. Khorana fiction and creative nonfiction works have been published in the Bellevue Literary Review, Annals of Internal Medicine and Health Affairs and selected for Best American Medical Writing 2009 (Kaplan,2009).
Education & Professional Highlights
Education & Fellowships
Fellowship - University of Rochester Medical Center
Rochester, NY USA
Residency - Millard Fillmore Gates Circle Hospital / Kaleida Health
Buffalo, NY USA
Medical Education - Baroda Medical College, The Maharaja Sayajirao University
Baroda, Gujarat, India
- Internal Medicine - Medical Oncology
Research & Publications
See publications for Alok Khorana, MD.
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 1/7/2022, Dr. Khorana has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Consulting and/or Speaking. Dr. Khorana receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:
- Pfizer, Inc.
- Anthos Therapeutics, Inc.
- Sanofi S.A.
- Bristol-Myers Squibb
- Bayer AG
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.